STRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Given the investor's beginner level, long-term strategy, and available investment range, Sutro Biopharma Inc. (STRO) is not a strong buy at this moment. The technical indicators are mixed, with no clear bullish signals, and the company's financial performance shows significant declines in revenue, net income, and EPS. While analyst ratings and price target upgrades are positive, the lack of recent news, no significant trading trends, and weak proprietary trading signals suggest a cautious approach. Holding off for now is recommended.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 49.753, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 20.257, and resistance is at 25.785. Overall, the technical indicators are mixed, with no strong bullish signals.
Analyst upgrades with significant price target increases, particularly highlighting the potential of STRO-004 and its favorable pre-clinical profile. The company's precision-engineered platform is seen as a differentiator.
The company's financial performance in Q4 2025 showed significant declines in revenue (-21.35%), net income (-35.45%), and EPS (-39.07%). No recent news or significant trading trends from hedge funds, insiders, or Congress. Post-market price change is -1.60%, reflecting weak sentiment.
In Q4 2025, revenue dropped to $11.65M (-21.35% YoY), net income dropped to -$46.76M (-35.45% YoY), and EPS dropped to -$5.35 (-39.07% YoY). Gross margin remained at 100%. Overall, financials indicate a challenging quarter with declining growth metrics.
Recent analyst upgrades are positive, with Deutsche Bank raising the price target to $55, Wells Fargo to $27, and H.C. Wainwright to $28. Analysts highlight the potential of STRO-004 and the company's platform as key drivers for future growth.
